Doctors Note Logo

Published on: 9/17/2026

Why would my doctor prescribe Farxiga if I don't have diabetes?

Farxiga (dapagliflozin) is approved for more than blood sugar control, so doctors often prescribe it to people without diabetes to treat heart failure or chronic kidney disease, where it has been shown to reduce hospitalizations, slow kidney decline, and lower the risk of cardiovascular death. Your prescription may also reflect risk factors such as protein in your urine, a reduced ejection fraction, high blood pressure, or a family history of kidney failure, and dosing, side effects like urinary tract or genital infections, and dehydration precautions differ depending on why it was prescribed. There are several important factors to consider, including how Farxiga interacts with diuretics and when it should be paused, so review the complete answer below before your next dose.

If you are unsure why this medication was recommended or you are noticing new symptoms like swelling, fatigue, dizziness, or changes in urination, it helps to organize what you are experiencing before you call your care team. A free, instant, online symptom check can help you clarify which of your symptoms may relate to your heart, kidneys, or the medication itself, and point you toward the right next step and the right questions to ask.

Last reviewed for medical accuracy: 09/17/2025

answer background

Explanation

Farxiga isn’t just for blood sugar control. Even if you don’t have diabetes, your doctor may prescribe Farxiga (dapagliflozin) to help protect your heart and kidneys. Here’s why.

Introduction to Farxiga
Farxiga belongs to a class of medications called SGLT2 inhibitors. It works by helping your kidneys remove extra salt and glucose through urine. While Farxiga was first approved to lower blood sugar in type 2 diabetes, large studies have shown it also benefits people with heart failure and chronic kidney disease—conditions that often occur without diabetes.

How Farxiga Works Beyond Blood Sugar
• Sodium-glucose cotransporter-2 (SGLT2) inhibition
– Blocks SGLT2 in kidney tubules
– Increases glucose and sodium excretion
– Reduces blood volume and pressure
• Hemodynamic effects
– Lowers preload and afterload on the heart
– Promotes mild diuresis without major electrolyte shifts
• Metabolic benefits
– May improve heart muscle energy use
– Lowers markers of kidney stress

Key Reasons for Prescribing Farxiga in Non-Diabetic Patients

  1. Heart Failure
    • HFrEF (Heart Failure with Reduced Ejection Fraction)
    – DAPA-HF trial: Farxiga cut the risk of heart-failure hospitalization or cardiovascular death by about 26% in patients with or without diabetes
    • HFpEF (Heart Failure with Preserved Ejection Fraction)
    – DELIVER trial: Farxiga reduced heart-failure events and death in people whose ejection fraction is ≥40%
    • Benefits you might notice
    – Fewer flare-ups of fluid overload (swelling, shortness of breath)
    – Better exercise tolerance
    – Lowered risk of emergency heart failure treatment

  2. Chronic Kidney Disease (CKD)
    • DAPA-CKD trial: Farxiga reduced the risk of worsening kidney function or kidney failure by about 39%, even in patients without diabetes
    • Slows loss of glomerular filtration rate (GFR)
    • Reduces albuminuria (protein in urine)
    • Keeps you off dialysis longer

  3. Blood Pressure and Weight
    • Modest drop in systolic blood pressure (3–6 mmHg)
    • Slight weight loss (1–3 kg), mainly due to fluid reduction

Who Might Be a Candidate
Doctors consider Farxiga for adults who have:

  • Chronic heart failure (HFrEF or HFpEF)
  • Chronic kidney disease (eGFR ≥25 mL/min/1.73 m2 and albuminuria)
  • Adequate kidney function and stable blood pressure
  • No history of recurrent urinary tract or genital infections

Common Questions About Farxiga Use

Q: “I don’t have diabetes—how can a blood-sugar drug help my heart and kidneys?”
A: The heart and kidneys share similar pathways. By blocking SGLT2, Farxiga reduces fluid overload, lowers blood pressure, and eases stress on both organs—benefits separate from blood sugar lowering.

Q: “Will Farxiga make me dehydrated?”
A: Farxiga causes mild diuresis. Staying hydrated and monitoring blood pressure can prevent dizziness or lightheadedness. Your doctor may adjust other diuretics if you take them.

Q: “How quickly will I feel better?”
A: Some patients notice improved energy or reduced swelling within weeks. Heart-failure and kidney-protection benefits continue over months to years.

Safety and Side Effects
Farxiga is generally well tolerated, but be aware of:
• Genital mycotic infections (yeast infections)
– More common in women but possible in men
– Good hygiene and prompt treatment usually prevent complications
• Urinary tract infections
– Report burning or urgency to your doctor early
• Volume depletion
– Dizziness, low blood pressure
– Drink water and report faintness
• Initial drop in eGFR
– Often stabilizes within a month
– Regular kidney function tests are important
• Rare: ketoacidosis, Fournier’s gangrene
– Extremely uncommon in non-diabetics
– Seek immediate care for severe abdominal pain, nausea, or signs of infection

Monitoring and Follow-Up
Your doctor will likely order:

  • Kidney function tests (eGFR, creatinine)
  • Electrolytes (sodium, potassium)
  • Blood pressure checks
  • Symptom reviews for swelling, fatigue, or infections

Free Online Symptom Check
If you’re curious whether your symptoms warrant a closer look, try a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a simple first step to understand your health concerns before your next appointment.

Tips for Getting the Most from Farxiga
• Take as prescribed, once daily, with or without food.
• Drink plenty of fluids, especially in hot weather or with exercise.
• Maintain good genital hygiene.
• Weigh yourself daily and report rapid gains (>2–3 lbs in 24 hours).
• Keep all follow-up lab appointments.

When to Call Your Doctor
Contact your healthcare provider if you experience:

  • Severe dizziness or fainting
  • Signs of severe dehydration (extreme thirst, dry mouth)
  • Unusual genital pain or swelling
  • Dark, cloudy, or foul-smelling urine
  • New or worsening shortness of breath

Conclusion
Farxiga offers heart and kidney protection that’s independent of its blood-sugar-lowering effects. If your doctor has prescribed Farxiga despite the absence of diabetes, it’s likely to reduce your risk of heart-failure hospitalizations and slow kidney disease progression. Stay hydrated, monitor for side effects, and keep up with scheduled lab tests to ensure the best results.

Always speak to a doctor about anything that could be life threatening or serious. And remember, if you’re wondering whether your symptoms need medical attention, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.

(References)

  • * Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Górriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjöström CD, Langkilde AM, Heerspink HJL. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234. PMID: 32862232; PMCID: PMC7538235.

  • * Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PMID: 32970396.

  • * Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD, Langkilde AM, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. PMID: 33338413.

  • * Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefánsson BV, Langkilde AM, Wheeler DC, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. J Am Soc Nephrol. 2021 Sep;32(9):2352-2361. doi: 10.1681/ASN.2021020167. Epub 2021 Jul 16. PMID: 34272327; PMCID: PMC8729835.

  • * Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM, DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27. PMID: 36027570.

  • * Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, Petersson M, Langkilde AM, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Sabatine MS, Shah SJ, Solomon SD, McMurray JJV. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022 Sep;28(9):1956-1964. doi: 10.1038/s41591-022-01971-4. Epub 2022 Aug 27. PMID: 36030328; PMCID: PMC9499855.

  • * Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH, Thuresson M, Bozkurt B. Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart Fail. 2023 Jan;11(1):1-14. doi: 10.1016/j.jchf.2022.08.009. Epub 2022 Sep 7. PMID: 36202739.

  • * Wu Q, Yao Q, Hu T, Yu J, Jiang K, Wan Y, Tang Q. Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2. Cell Rep Med. 2023 Dec 19;4(12):101334. doi: 10.1016/j.xcrm.2023.101334. PMID: 38118414; PMCID: PMC10772464.

  • * Cox ZL, Collins SP, Hernandez GA, McRae AT 3rd, Davidson BT, Adams K, Aaron M, Cunningham L, Jenkins CA, Lindsell CJ, Harrell FE Jr, Kampe C, Miller KF, Stubblefield WB, Lindenfeld J. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. J Am Coll Cardiol. 2024 Apr 9;83(14):1295-1306. doi: 10.1016/j.jacc.2024.02.009. PMID: 38569758.

  • * Hu H, Li W, Hao Y, Peng Z, Zou Z, Wei J, Zhou Y, Liang W, Cao Y. The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy. Cell Rep Med. 2024 Aug 20;5(8):101690. doi: 10.1016/j.xcrm.2024.101690. PMID: 39168099; PMCID: PMC11384938.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.